Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Oil Prices Slide on US-Iran Talks, Dollar Strength and Profit-Taking Pressure 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Drugmakers including Pfizer Inc, GlaxoSmithKline PLC , Bristol Myers Squibb, AstraZeneca PLC and Sanofi SA will raise prices in the US on over 350 unique drugs in early January.
The increases are in preparation for the Inflation Reduction Act (IRA), which allows the government's Medicare health program to negotiate prices for some drugs starting in 2026.
The pharmaceutical industry is also dealing with inflation and supply chain constraints that increased manufacturing costs.
The price hikes are based on list prices, which do not account for other discounts or rebates to pharmacy benefit managers.
According to data released by 46brooklyn, a drug pricing non-profit affiliated with 3 Axis, drugmakers increased prices on more than 1,400 pharmaceuticals in 2022. Since 2015, there have been the most rises.
According to Antonio Ciaccia, president of 3 Axis, drugmakers have concentrated on releasing their medications at higher prices due to the concentration on annual price hikes.
More drug prices are likely to be announced over the course of January - historically the biggest month for drugmakers to raise prices.
Pfizer has so far disclosed the biggest price hikes, with 89 different prescription names seeing a rise in price in addition to an extra 10 drug brands at its Hospira division.
Then came GSK, which has already announced hikes for 26 different medications, including nearly a 7% rise for its well-known shingles vaccine Shingrix.
